PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction.

Abstract The standardization for the clinical use of drug therapy for cerebral infarction (CI) has not yet determined in some aspects. In this paper, we discussed the efficacies of different drug therapies (aspirin, aspirin plus dipyridamole, aspirin plus clopidogrel, aspirin plus warfarin, cilostazol, warfarin, and ticlopidine) for CI.
PMID
Related Publications

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.

Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.

Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons.

The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29595635
OWN - NLM
STAT- MEDLINE
DCOM- 20180405
LR  - 20180405
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 13
DP  - 2018 Mar
TI  - Aspirin plus dipyridamole has the highest surface under the cumulative ranking
      curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse
      event rate among 7 drug therapies in the treatment of cerebral infarction.
PG  - e0123
LID - 10.1097/MD.0000000000010123 [doi]
AB  - BACKGROUND: The standardization for the clinical use of drug therapy for cerebral
      infarction (CI) has not yet determined in some aspects. In this paper, we
      discussed the efficacies of different drug therapies (aspirin, aspirin plus
      dipyridamole, aspirin plus clopidogrel, aspirin plus warfarin, cilostazol,
      warfarin, and ticlopidine) for CI. METHODS: We searched databases of PubMed and
      Cochrane Library from the inception to April, 2017, randomized controlled trials 
      (RCTs) met the inclusion and exclusion criteria were enrolled in this study. The 
      network meta-analysis integrated evidences of direct and indirect comparisons to 
      assess odd ratios (OR) and surface under the cumulative ranking curves (SUCRA)
      value. RESULTS: Thirteen eligible RCTs including 7 drug therapies were included
      into this network meta-analysis. The network meta-analysis results showed that CI
      patients who received aspirin plus dipyridamole presented lower mortality when
      compared with those received aspirin plus clopidogrel (OR = 0.46, 95% CI =
      0.18-0.99), indicating aspirin plus dipyridamole therapy had better efficacy for 
      CI. As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event
      (AE) rate, there were no significant differences of efficacy among 7 drug
      therapies. Besides, SUCRA values demonstrated that in the 7 drug therapies,
      aspirin plus dipyridamole therapy was more effective than others (mortality:
      80.67%; ICH: 76.6%; AE rate: 90.2%). CONCLUSIONS: Our findings revealed that
      aspirin plus dipyridamole therapy might be the optimum one for patients with CI, 
      which could help to improve the survival of CI patients.
FAU - Zhang, Jian-Jun
AU  - Zhang JJ
AD  - Department of Pharmacy, Liaocheng People's Hospital, Liaocheng, P.R. China.
FAU - Liu, Xin
AU  - Liu X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Hematologic Agents)
RN  - 0 (Tetrazoles)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 64ALC7F90C (Dipyridamole)
RN  - A74586SNO7 (clopidogrel)
RN  - N7Z035406B (cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - AIM
SB  - IM
MH  - Aspirin/*administration & dosage/*adverse effects
MH  - Cerebral Infarction/*drug therapy/mortality
MH  - Dipyridamole/administration & dosage/*adverse effects
MH  - Drug Therapy, Combination
MH  - Hematologic Agents/*adverse effects
MH  - Humans
MH  - Intracranial Hemorrhages/chemically induced/*epidemiology
MH  - Tetrazoles/administration & dosage/adverse effects
MH  - Ticlopidine/administration & dosage/adverse effects/analogs & derivatives
MH  - Warfarin/administration & dosage/adverse effects
EDAT- 2018/03/30 06:00
MHDA- 2018/04/06 06:00
CRDT- 2018/03/30 06:00
PHST- 2018/03/30 06:00 [entrez]
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2018/04/06 06:00 [medline]
AID - 10.1097/MD.0000000000010123 [doi]
AID - 00005792-201803300-00008 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Mar;97(13):e0123. doi: 10.1097/MD.0000000000010123.